US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% SNDK $1,704.16 ▼-0.92%
FinancialContent

Articles published by Sesen Bio, Inc.

News headline image
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Receives NASDAQ Delisting Notice
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma Therapeutics
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Reiterates Confidence in Pending Merger with Carisma Therapeutics
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Sesen Bio and Carisma Therapeutics Announce Merger Agreement
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum™
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Dr. Thomas Cannell, President and CEO of Sesen Bio, to Participate in Fireside Chat at the 2021 Jefferies Virtual Healthcare Conference
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN
News headline image
Dr. Thomas Cannell, President and CEO of Sesen Bio, and Dr. Michael Jewett, FRCSC, FACS, to Participate in Canaccord Genuity “Horizons in Oncology” Virtual Conference
From Sesen Bio, Inc.
Via Business Wire
Tickers SESN